University of California Los Angeles
Los Angeles, California, United States
Dr. Cloughesy is a distinguished professor of Neurology and Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA. He is the director of the UCLA neuro-oncology program and co-director of the UCLA Brain Tumor Center. His research includes therapeutic, imaging, translational and basic investigations. His focus on clinical trials in brain cancer involves novel clinical trial design, incorporation of biomarkers and development of new biomarkers. He provided principal leadership for the accelerated approval and the conversion to full approval of the drug bevacizumab for recurrent glioblastoma. He has authored or co-authored over 450 peer-reviewed articles on brain cancer and has a Google Scholar H index of 129. He was selected as the Victor Levin Award through the Society of Neuro-oncology in 2021 and was elected to the Association of American Physicians in 2022. He federal and foundation funding, including a recent Brain Cancer SPORE at UCLA where he co-Leads a project and the administrative core. He is the global principal investigator for GBM AGILE which was created as a master protocol utilizing an adaptive Bayesian approach for late stage global glioblastoma clinical development. He is co-founder, board member and CMO of the 501c3 Global Coalition for Adaptive Research which sponsors GBM AGILE in addition to other Adaptive Platform Trials for other rare and common diseases. He is a co-Inventor of a highly brain penetrant EGFR inhibitor, ERAS-801, developed for glioblastoma and currently in phase I studies in glioblastoma; co-founder, member of the board and scientific advisory board for Katmai Pharmaceuticals. He serves on the Scientific Advisory Board for Break Through Cancer 501c3. He played a principal role in the clinical development of vorasidenib and was the US PI for the INDIGO study.
